ArticleJAMA network open2026
Body Mass Index at Diagnosis, Prediagnostic Weight Loss, and Survival in Colorectal Cancer.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Evidence on the association of excess adiposity with colorectal cancer (CRC) prognosis is conflicting, with some studies reporting better survival in patients with elevated body mass index (BMI)-often referred to as the obesity paradox. Objective: To investigate to what extent the obesity paradox can be explained by prediagnostic cancer-associated weight loss. Design, Setting, and Participants: This multicenter, population-based case-control study with prospective follow-up included patients aged 30 years or older with histologically confirmed CRC who were recruited from more than 20 hospitals in southwest Germany between 2001 and 2016, with survival follow-up through September 2018. Analysis was conducted from September 2025 to June 2026. Exposure: BMI at diagnosis (underweight, BMI <18.5; normal weight, BMI 18.5 to <25.0; overweight, BMI 25.0 to <30.0; obesity, BMI ≥30.0), and percent weight change during the 5 to 14 years preceding diagnosis, both derived from self-reported height and body weight. Main Outcomes and Measures: Overall, CRC-specific, and recurrence-free survival were assessed using Cox proportional hazards regression models adjusted for demographic and lifestyle factors, tumor characteristics, and comorbidities, estimated as hazard ratios (HRs) with 95% CIs. Results: Among 5521 patients with CRC (2159 female [39%]; median [IQR] age at diagnosis, 69 [61-76] years), 2429 deaths occurred during a median (IQR) follow-up of 5.2 (3.4-9.9) years, including 1381 CRC-related deaths. Compared with patients with normal weight at diagnosis, those who had overweight had modestly higher overall survival (HR, 0.89; 95% CI, 0.81-0.98), while no association was observed for obesity. Prediagnostic weight loss of more than 10% was associated with worse survival (HR, 1.55; 95% CI, 1.39-1.72). Upon mutual adjustment for at-diagnosis BMI and prediagnostic weight change, associations for overweight and obesity were attenuated to null. Conclusions and Relevance: In this case-control study with prospective follow-up of patients with CRC, the obesity paradox appeared to be largely attributable to prediagnostic cancer-associated weight loss. The apparent survival advantage associated with overweight and obesity at diagnosis should not be interpreted as evidence to encourage weight gain for patients with healthy weight or to revise existing survivorship recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.